Interim CEO Martin Zuegel Buys ACIU Shares
Martin Zuegel, Interim CEO of ACIU, acquired 33,136 shares on June 11, 2026.
Key Points
- On June 11, 2026, Martin Zuegel, Interim CEO of ACIU, purchased 33,136 shares.
- ACIU shares are trading at $2.31, with active institutional interest from BVF Inc/IL and BlackRock, Inc.
- Analysts from BTIG and HC Wainwright maintain a 'buy' rating with price targets of $8 and $12.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martin Zuegel, the Interim CEO of ACIU, bought 33,136 shares of the company on June 11, 2026. This insider purchase comes as the stock trades at $2.31 per share.
Other Institutional Activity in ACIU
Institutional investors have been active in ACIU. BVF Inc/IL holds a significant position with 19,822,436 shares valued at about $54.5 million. BlackRock, Inc. increased its stake by 22,109 shares to a total of 524,278 shares worth around $1.44 million. Conversely, Millennium Management LLC decreased its holdings by 140,685 shares, bringing its total to 792,657 shares valued at approximately $2.18 million. Renaissance Technologies LLC also reduced its position by 44,500 shares, leaving it with 624,367 shares worth about $1.72 million.
AC Immune SA Stock Down 11.3%
ACIU shares are trading around $2.31. The company has attracted attention from various institutional investors, indicating active interest in its stock.
Insider Buying and Selling at AC Immune SA
On June 11, 2026, several insiders, including Martin Zuegel, made significant purchases. Zuegel acquired 33,136 shares, while other insiders like Renee Aguiar-Lucander and Carl Howard June also bought shares, with Renee acquiring 38,889 shares and Carl purchasing a total of 55,457 shares.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on ACIU. On March 16, 2026, BTIG reiterated its 'buy' rating with a price target of $8. HC Wainwright & Co. also maintained its 'buy' rating with a higher target of $12. The consensus among analysts remains optimistic, with a strong 'buy' recommendation.
About ACIU
ACIU is a biotechnology company focused on developing treatments for neurodegenerative diseases. It is headquartered in Switzerland and aims to advance medical research in its field. The company collaborates with various partners to bring innovative therapies to market.
Bottom Line
Martin Zuegel's purchase of ACIU shares signals confidence in the company's future. Institutional investors continue to show interest, and analysts maintain favorable ratings. While insider transactions provide insights, they are not necessarily indicative of future stock performance.
Get AC Immune SA alerts
New 13F filings, insider trades, and analyst moves on $ACIU, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.